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Abstract: In our retrospective cohort study, we evaluated trends in pharmacist-administered pediatric influenza vaccination rates in the United States and corresponding state-level pharmacist
pediatric vaccination authorization models, including minimum age requirements, vaccination protocols, and/or prescription requirements. An administrative health claims database was used to
capture influenza vaccinations in children less than 18 years old with 1 year of continuous enrollment
and joinpoint regression was used to assess trends. Of the 3,937,376 pediatric influenza vaccinations identified over the study period, only 3.2% were pharmacist-administered (87.7% pediatrician
offices, 2.3% convenience care clinics, 0.8% emergency care, and 6.0% other locations). Pharmacistadministered pediatric influenza vaccination was more commonly observed in older children (mean
age 12.65 ± 3.26 years) and increased significantly by 19.2% annually over the study period (95%
confidence interval 9.2%-30.2%, p < 0.05). The Northeast, with more restrictive authorization models,
represented only 2.2% (n = 2816) of all pharmacist-administered pediatric influenza vaccinations. Utilization of pharmacist-administered pediatric influenza vaccination remains low. Providing children
with greater access to vaccination with less restrictions may increase overall vaccination rates. Due to
the COVID-19 pandemic and the Public Readiness and Emergency Preparedness Act, pharmacists
will play a major role in vaccinating children.
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1. Introduction

Publisher’s Note: MDPI stays neutral

Although annual influenza vaccine is recommended by the Centers for Disease Control
and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP)
for children 6 months and older [1–6], there is continued hesitancy towards influenza
vaccination [7]. The CDC has consistently reported pediatric vaccination rates that are lower
than the Healthy People 2020 target of 70% for children aged 6 months through 17 years [8,9],
potentially due to barriers in access [10]. According to the National Immunization Survey
(NIS), a national telephone survey conducted by the CDC to assess vaccination coverage
among children (6 months through 17 years) [11], pediatric influenza vaccination rates over
the past decade have increased from 51.0% in 2010–2011 to 63.8% in 2019–2020 [12].
While pediatric vaccines are often administered in pediatrician offices by nurses, nurse
practitioners, medical assistants, and physician’s assistants, under the supervision of a
physician, pharmacists have been approved influenza vaccinators in all 50 states since
2009 [13]. However, regulations enabling pharmacist-administered vaccination also carry
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restrictions, such as state-specific minimum age requirements and other regulatory limitations, including restricted lists of allowed vaccinations under these mandates [14–16].
Vaccination outside of pediatrician offices improves vaccine access through increased convenience, with expanded hours and without the need for an appointment [16]. Additionally,
93% of patients live within five miles of a pharmacy and most patients have positive
experiences with their pharmacy [17,18].
To date, there are limited published estimates of pharmacist-administered pediatric
influenza vaccination. According to NIS-Flu, pharmacy vaccination was reported for 5.5%
of pediatric influenza vaccinations in the 2017–2018 influenza season (66.8% doctor’s offices,
16.2% clinics and health centers, 4.3% hospitals, 3.8% schools. 1.9% health departments, and
1.5% other setting) [19]. Due to the limitations of NIS-Flu, including overestimation of pediatric
influenza vaccination and other biases due to the nature of survey methods [11], it is unclear
whether these estimates of pharmacist-administered vaccination are accurate. Further, statelevel variations in pharmacist-administered pediatric influenza vaccination remain unknown,
as does the influence of state-level pharmacist vaccination authorization models.
As such, the objective of this study was to evaluate state-level pharmacist pediatric
vaccination authorization models alongside state-level pharmacist-administered pediatric
influenza vaccination rates in an administrative health claims database and assess time
trends in pharmacist-administered pediatric influenza vaccination.
2. Materials and Methods
The distribution of vaccine providers among vaccinated children using an administrative health claims database with enrollees from all 50 states and the District of Columbia, the
Optum Clinformatics® Data Mart (OptumInsight, Eden Prairie, MN, USA) was assessed.
Using a retrospective cohort study design, pediatric influenza vaccinations by vaccine
provider setting and corresponding variations in patient characteristics were evaluated.
The study population included children with an influenza vaccination record between
1 July 2010 to 30 June 2017 identified from Current Procedural Terminology, 4th Edition
(CPT® ) procedure codes found in Supplementary Table S1 and under 18 years of age at
the time of the influenza vaccination claim. Vaccinations were assigned to influenza seasons, where time was divided into 12-month periods from 1 July through 30 June of the
following year [20]. For each season, pediatric patients with full continuous enrollment for
the 12 months of that season and with at least one influenza CPT® code, were for selected
for inclusion [20]. Only the first influenza vaccination within a season was included, while
patients with missing year of birth, state, or sex were excluded.
Vaccine provider setting was categorized as pediatrician offices, which included family
medicine and primary care settings, pharmacist-administered, convenience care clinic,
emergency care, and other, which included locations such as schools or other immunization
centers. Of note, pharmacy-based vaccination did not include healthcare clinics located in
retail pharmacies (e.g., CVS MinuteClinic) as those were categorized under convenience
care. Within each vaccine provider setting, we assessed the distribution of age and age
group, sex, region, and pharmacist-authorization minimum age restrictions. Both mean
and median age were assessed, as well as distribution by age groups per the NIS-Flu
categorization of 6–23 months, 2–4 years, 5–12 years, and 13–17 years [19]. States were
grouped into regions per the 2010 United States Census Bureau of Regions and Division [21]
categorizations, as regional vaccination coverage can vary [22].
A grey literature search was performed to identify state-level regulations regarding
pharmacist-authority to administer influenza vaccines in children. Grey literature search
methods consisted of a Google search of key terms, including “pharmacist administered
pediatric influenza vaccination” and “minimum age restrictions”. Search results were
assessed for state-level regulations. One document was selected for inclusion after fulltext review, authored by the American Pharmacists Association (APhA) and the National
Alliance of State Pharmacy Associations (NASPA), due to the corresponding timeframe
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of the document and the study data [14]. Minimum age restrictions were assessed for all
authorization models within each state.
The distribution of influenza vaccine provider setting among vaccinated children, and
calculated pharmacist-administered pediatric influenza vaccination rates for each state (the
proportion of vaccinated children with pharmacy provider setting within each state) was
assessed. Pharmacist-administered pediatric influenza vaccination rates were then averaged
among states with corresponding authorization models and minimum age requirements.
Statistical Analysis
Demographic characteristics of vaccinated children in each provider setting were
compared with the pediatrician office setting using chi-square tests, t-test, or Wilcoxon
rank sum test, as appropriate, in SAS (version 9.4, SAS Institute Inc., Cary, NC, USA). Time
trends in pediatric vaccination were assessed by vaccination provider setting with joinpoint
regression, over the seven vaccination seasons with each season being an equally weighted
interval. Average annual percent change (AAPC) and corresponding 95% confidence intervals by vaccination provider setting were calculated using the Joinpoint Regression
Program, version 4.7.0.0 (National Cancer Institute, Bethesda, MD, USA). Statistical significance was considered p < 0.05.
3. Results
3.1. Pharmacist-Administered Pediatric Influenza Vaccination Rates
This study included 3,937,376 influenza vaccinations among children over seven influenza seasons, from 2010 to 2017 (Table 1). Of the total influenza vaccinations, most occurred
in pediatrician offices (87.7%, n = 3,451,658), followed by pharmacist-administered (3.2%,
n = 125,709), convenience care (2.3%, n = 90,304), and emergency care (0.8%, n = 32,499).
Table 1. Pediatric influenza vaccinations by vaccine provider setting.
Demographic Characteristics
and Authorization Models

Pediatrician Office
n = 3,451,658
(87.7%)

Pharmacy
n = 125,709
(3.2%)

Convenience Clinic
n = 90,304
(2.3%)

Emergency Care
n = 32,499
(0.8%)

Other
n = 237,206
(6.0%)

Age (Mean ± SD)

7.04 ± 4.81

12.65 ± 3.26 *

9.73 ± 4.23 *

8.21 ± 4.64 *

8.37 ± 4.90 *

Age Group †
6 months–2 years
2–4 years
5–12 years
13–17 years

768,750 (22.3%)
520,856 (15.1%)
1,579,900 (45.8%)
582,152 (16.9%)

87 (0.1%) *
1314 (1.1%) *
53,502 (42.6%) *
70,806 (56.3%) *

2784 (3.1%) *
8775 (9.7%) *
51,919 (57.5%) *
26,826 (29.7%) *

4092 (12.6%) *
4221 (13.0%) *
17,178 (52.9%) *
7008 (21.6%) *

35,227 (14.9%) *
28,300 (11.9%) *
115,465 (48.7%) *
58,214 (24.5%) *

Sex †
Female
Male

1,687,410 (48.9%)
1,764,248 (51.1%)

62,095 (49.4%) *
63,614 (50.6%) *

45,513 (50.4%) *
44,791 (49.6%) *

15,959 (49.1%)
16,540 (50.9%)

116,650 (49.2%) *
120,556 (50.8%) *

Region †
Midwest 1
Northeast 2
South 3
West 4

969,480 (28.1%)
486,435 (14.1%)
1,361,550 (39.5%)
634,193 (18.4%)

28,548 (22.7%) *
2816 (2.2%) *
56,517 (45.0%) *
37,828 (30.1%) *

24,134 (26.7%) *
6934 (7.7%) *
47,898 (53.0%) *
11,338 (12.6%) *

6178 (19.0%) *
1775 (5.5%) *
8288 (25.5%) *
16,258 (50.0%) *

82,370 (34.7%) *
17,536 (7.4%) *
50,333 (21.2%) *
86,967 (36.7%) *

822121 (23.8%)
80514 (2.3%)

46238 (36.8%) *
7509 (6.0%) *

14429 (16.0%) *
4899 (5.4%) *

17369 (53.4%) *
85 (0.3%) *

94696 (39.9%) *
3119 (1.3%) *

State-Level Pharmacist
Authorization Model, Age
Restrictions †
No age restriction
Min age 2–4 years old
Min age 5–12 years old,
Any age with Rx
Min age 5–12 years old
Min age 13–17 years,
Any age with Rx
Min age 13–17 years old 5
Min 18 years old

784427 (22.7%)

39765 (31.6%) *

21981 (24.3%) *

3477 (10.7%) *

33708 (14.2%) *

1031281 (29.9%)

22207 (17.7%) *

23692 (26.2%) *

7701 (23.7%) *

79558 (33.5%) *

175394 (5.1%)

6099 (4.9%) *

8103 (9.0%) *

863 (2.7%) *

10549 (4.5%) *

103572 (3.0%)
454349 (13.2%)

2652 (2.1%) *
1239 (1.0%) *

5086 (5.6%) *
12114 (13.4%) *

363 (1.1%) *
2641 (8.1%) *

3003 (1.3%) *
12573 (5.3%) *

†

No. (%). * p < 0.05. 1 Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota,
South Dakota, Nebraska, Kansas. 2 Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut,
New York, New Jersey, Pennsylvania. 3 West Virginia, District of Columbia (DC), Virginia, North Carolina,
Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas,
Louisiana, Oklahoma, Texas. 4 Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon,
California, Alaska, Hawaii, New Mexico, Arizona. 5 Includes Hawaii, where a prescription is required for
pharmacist-administered influenza vaccination.
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Figure 1. Median age of pediatric influenza vaccination by vaccine provider setting.
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Most
vaccinations occurred in the South, for vaccination in the pediatrician office setting (39.5%),
pharmacy (45.0%), and convenience care (53.0%), whereas most vaccinations in emergency
care (50.0%) and other settings (36.7%) occurred in the West. Of all pharmacist-administered
pediatric influenza vaccinations, only 2.2% (n = 2816) occurred in the Northeast, as Connecticut, Massachusetts, New York, and Vermont did not allow pharmacist-administered
pediatric influenza vaccination.
Over the study period, the average annual percent change in pharmacist-administered
pediatric influenza vaccination increased significantly by 19.2% (95% CI 9.2 to 30.2, p < 0.05),
from 1.5% in the 2010–2011 season to 4.2% in the 2016–2017 season (Figure 2). During
the same period, the average annual percent change in pediatric influenza vaccination in
pediatrician office decreased significantly by 0.9% (95% CI −1.3 to −0.5, p < 0.05).
3.2. Pharmacist-Administered Pediatric Influenza Vaccination Authorization Models
In the United States, the legislature of each state grants immunization authority
to pharmacists under an approved scope of practice. There are three main state-level
authorization models under which pharmacists can administer vaccinations (Table 2):
prescription from physician provider, vaccination protocol, or pharmacist independent
authority (neither physician prescription nor protocol required). A vaccination protocol
specifies which vaccines can be administered under the protocol and vaccine administration
procedures, including age limitations, usually agreed upon between state-level pharmacist
groups, state-level physician groups, and the state public health department. Under a
vaccination protocol, no prescription is required. In an independent authority model,
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cination
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[23].
6 months *

Virginia 1,3

3

Arizona 1,2
California 1,2

5.6%

6

Idaho

2.7%

7

Louisiana 1,3
Maine
Oregon 1,3
Wyoming

3.3%

9

Maryland

2.9%

12

Montana
New Jersey 1,3
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1.4%
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Table 2. Cont.

Authorization Model

Patient Age
limitations

State(s)

Average
Pharmacist-Administered
Pediatric Influenza
Vaccination Rates, by
Authorization Model and age
RESTRICTION

Any Age

Alabama
California 1,2
Colorado
Delaware
Michigan
Mississippi
Nebraska
Nevada
Oklahoma
South Dakota
Tennessee
Utah
Washington

4.5%

5

North Dakota

0.3%

Average
Pharmacist-Administered
Pediatric Influenza
Vaccination Rates, by
Authorization Model

1,2

Protocol 2

6

Arizona
Iowa 2,3
Kansas
Minnesota
Wisconsin

3.7%

7

Arkansas
Ohio
Texas 2,3

3.6%

9

Kentucky 2,3
Pennsylvania
Rhode Island

1.3%

10

Illinois

3.3%

11

Indiana 2,3

3.3%

12

District of Columbia 2,3
Missouri 2,3

2.2%

13

Georgia 2,3

3.0%

14

North Carolina

2.3%

Any Age

District of Columbia 2,3
Georgia 2,3
Indiana 2,3
Iowa 2,3
Kentucky 2,3
Louisiana 1,3
Missouri 2,3
Oregon 1,3
South Carolina 1,3
Texas 2,3
Virginia 1,3

3.2%

6

New Jersey 1,3

0.9%

14

Hawaii

0.1%

Prescription 3

3.5%

2.8%

Note: Pharmacist-administered pediatric influenza vaccination authorization models as of July 2016 [14]. Authorization models are not mutually exclusive for each state, as states may have different authorization models for
different age groups. * Influenza vaccine is recommended in children 6 months of age and older. 1 Pharmacists
have authority to administer vaccines without a protocol or prescription. 2 Vaccination protocol specifies vaccine
administration procedures usually agreed upon between state-level pharmacist and physician groups and the
state public health department. 3 Prescription from physician provider is required prior to administration of
vaccine by pharmacist.

Regardless of pharmacist authorization models (Table 2), the minimum age requirements allowing pharmacists to vaccinate against influenza vary by state (Figure 3). Arizona,
where pharmacists are authorized to administer influenza vaccinations under two autho-
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rization models, the least restrictive being pharmacist independent authority beginning
at 3 years of age, had the highest percent of children vaccinated by a pharmacist at 7.8%
(Figure 3). Following Arizona were states where there is no age limit; New Mexico (6.9%),
Colorado (6.6%), Nevada (6.1%), Mississippi (6.1%), Oklahoma (5.9%), Michigan (5.5%),
and Nebraska (5.0%). The pharmacist-administered influenza vaccination rate in Texas
was 5.6%, which allows pharmacist-administered influenza vaccination for children 7 years
and older under a protocol and at any age with a prescription. Hawaii had the lowest pharmacist-administered influenza vaccination (0.1%), as the mandate only allows
pharmacist-administered influenza vaccination in children 14 years and older with a physiVaccines 2022, 10, x FOR PEER REVIEW
8 of 12
cian prescription. As of July 2016 [14], and prior to the Public Readiness and Emergency
Preparedness Act [24], six states did not allow pharmacist-administered influenza vaccination for children of any age, including Connecticut, Florida, Massachusetts, New York,
Vermont, and West Virginia.
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tions around pharmacist-administered pediatric vaccination. States with more restrictions
and older minimum age requirements, had lower rates of pharmacist-administered influenza immunization.
According to NIS-Flu data for the 2017–2018 influenza season, 5.5% of all children
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limitations around pharmacist-administered pediatric vaccination. States with more restrictions and older minimum age requirements, had lower rates of pharmacist-administered
influenza immunization.
According to NIS-Flu data for the 2017–2018 influenza season, 5.5% of all children ages
6 months to 17 years old were immunized in a pharmacy setting, and 66.8% of children were
vaccinated in their doctor’s office [19], while 28.3% of adults were vaccinated in a pharmacy
and 34.7% in physicians’ offices [25]. NIS-Flu is a national dual landline and cellular listassisted random-digit-dialed telephone survey of households. This self-reported survey
data is subject to recall bias and non-response bias from low response rates [11]. The
findings presented from this cohort study were from administrative claims data from a
commercially insured population with records of actual influenza vaccine administrations
by provider setting and are not subject to survey data biases.
As also reported by NIS-Flu data, influenza vaccine setting varied by age group; for
example children less than 5 years old utilized pediatrician offices more frequently than
other settings and children 13–17 years old utilized a pharmacy setting more frequently [19].
This is noted in the findings presented here as well, as 98.9% of children that were vaccinated
in a pharmacy were 5–17 years old, with 56.3% in the 13–17-year age group versus 16.9% in
the 13–17 years old age group for pediatrician offices. Administration of annual influenza
vaccine typically occurs around the same time every year, in late fall or early winter, which
may not align with a child’s annual routine examination. As children get older, they are less
likely to receive the influenza vaccine in general. For example, in the 2015–2016 influenza
season, vaccination coverage rates within age groups were as follows; 6 months-23 months
75.3%, 2–4 years 66.8%, 5–12 years 61.8%, and 13–17 years 46.8% [25]. This has been a
consistent trend since 2010 according to NIS-Flu data [19]. This may be due to a decrease
in the number of physician visits as children get older, and therefore increased interest in
vaccination outside of that setting, such as a pharmacy, would provide.
A main objective of pharmacist-administered influenza immunization is to expand
access to vaccination through increased accessibility, convenience, extended hours, and
widespread locations [8] for patients who find it difficult to reach traditional healthcare
services, which could in turn increase vaccination coverage for all ages [18]. Pharmacies are
open for longer hours during the week and are also available on weekends and holidays. A
study from the 2011–2012 influenza season estimated that over 30% of all adult vaccinations administered at a Walgreens pharmacy chain were during evenings, weekends, or
holidays [26]. Another important role pharmacists play is through vaccine advocacy [27].
A study conducted among adults showed that pharmacists were more successful than traditional healthcare providers in administering vaccines to patients that were not current in
their immunizations after performing an immunization needs assessment [8]. However, a
scenario where pharmacists require a prescription from a healthcare provider to administer
vaccines to patients, particularly in children, can be more costly and less efficient [23].
Increasing influenza vaccination among children is critical to controlling influenza
outbreaks. It has been found that vaccinating children, in addition to protecting other children, protects the entire community by limiting the transmission of the virus, in particular
to vulnerable populations such as the elderly and immunocompromised [28]. Expansion of
the ability for pharmacists to administer vaccines and increase vaccination rates among
children, for influenza and other epidemics, is critical for public health.
As of August 2020, pharmacists in all states have been authorized by the U.S. Health
and Human Services Department (HHS) to administer any FDA authorized vaccines to
children aged 3 to 18 under the “Third Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID–19”
(PREP Act) for the duration of the COVID-19 pandemic [24]. Due to the current COVID-19
pandemic, there has been an alarming decline in routine pediatric vaccines due to decreased pediatric physician visits and changes in healthcare access (such as closed offices
or limited hours, and corresponding increases in virtual visits) [24,29]. Data collected from
the Vaccines for Children program, a national program that provides vaccines to approx-
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imately 50% of children in the United States [29], showed that physicians participating
in the program ordered approximately 2.5 million fewer non-influenza routine vaccines
and 250,000 less measles-containing vaccines, and the decline was more prominent in
children 2–18 years old [29,30]. In the declaration, pharmacists are recognized as being
well positioned to expand access to all childhood vaccinations, which can help combat the
public health threat of declining vaccination rates [24].
As this amendment is recent and parents may not be aware of this change, it is unclear
to what extent parents will elect to have their children vaccinated by a pharmacist. National
and community-level campaigns to raise awareness about the availability and convenience
of pediatric vaccination at local pharmacies may increase uptake. Future efforts should
monitor uptake of pharmacist-administered pediatric vaccination to determine utilization
rates, and whether increased vaccination by pharmacists compensates for reductions in
pediatrician office vaccinations. It is possible that societal vaccination practices may shift
as a result of this expansion in care, similar to changes observed in satisfaction with and
therefore preference in some cases for virtual healthcare [31]. It remains unknown how long
pharmacist-administered vaccination authorization will remain under the PREP Act. Studying its long-term impacts will be important for advocacy efforts of continued expanded
access to vaccination for children in the United States at their local pharmacies, particularly
if pharmacists become the primary vaccine provider for pediatric COVID-19 vaccines.
Limitations
The population studied here was limited to pediatric patients from one administrative
health claims database within the U.S., compiled from vaccination procedure codes. As
such, this study did not assess influenza vaccination by provider setting among pediatric
patients with Medicaid, which is estimated to include approximately 30 million children
nationally, or other private health plans [32], and distributions by vaccine provider may
vary in these populations. Missing from this cohort are influenza vaccinations that were not
processed through health insurance, such as through free public health clinics. Due to the
nature of the database, age was calculated using the date of vaccination and the patient’s
year of birth. In patients that are vaccinated in early fall and have birthdays occurring later
in the year, the patient would be considered one year older if they were vaccinated before
their birthday. The study relies on the accuracy and consistency of provider categorization
in the source data to indicate vaccine administration setting. Additionally, the study
population available from this database is now several years old, and future research should
evaluate whether these trends are still observed in more current populations. Vaccinations
in other locations, including non-specific locations were uncommon, encompassing 6.0%
of pediatric influenza vaccination in this study population. Overall pediatric influenza
vaccination rates vary by state [19], as did the proportion of children within this dataset
of the total state pediatric population, which we did not assess in this study. Race and
ethnicity were not available from the data source, and therefore, could not be assessed.
Pharmacist authorization models were assessed as of July 2016, and therefore changes in
authorization models may have occurred over the 7-year period when pediatric influenza
vaccination administrative claims were assessed.
5. Conclusions
Although pharmacist-administered influenza vaccination has been allowed in all
50 states for over 10 years [13], various state-level restrictions on pharmacist-administered
pediatric influenza vaccination, such as protocols, prescription requirements, and minimum
age restrictions, impact uptake of pharmacist-administered pediatric influenza vaccination,
as we observed the lowest pharmacist-administered influenza vaccination rates in states
with the most restrictive laws. Of the nearly 4 million, pediatric influenza vaccinations
included in this study, only 3.2% were pharmacist-administered. However, utilization of
pharmacists as influenza vaccinators of children increased significantly by 19.2% each year
over our 7-year study period, with most pharmacist-administered influenza vaccinations
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being administered to older children (mean age, 12.65 ± 3.26). Providing children with
greater access to vaccinations with fewer restrictions could help increase influenza vaccination rates to get closer to the Healthy People 2020 target of at least 70% for children [9].
Additionally, during the ongoing COVID-19 pandemic, pharmacists will be instrumental
for overcoming the profound decrease in all pediatric vaccination rates observed during
the pandemic [24]. Future research should evaluate uptake of pharmacist-administered
pediatric vaccination for influenza, other childhood vaccines, and pediatric COVID-19
vaccination when such data become available.
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